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Abstract-The responsiveness to IL-4 with and without costimulation with anti-IgM antibodies or 
phorbolester was studied in 35 cases of low grade non-Hodgkin Iymphoma by analyzing enhancement 
of CD23 and HLA dass li expression. The predominant phenotype responds directly to IL-4. Separate 
differentiation states can be distinguished according to coordinate or differential upregulation of 
CD23 and HLA dass II molecules by IL-4 alone, and differences in responsiveness to anti-IgM 
antibodies. A particular subgroup of B-lymphoma cells defines a separate stage of B-eeil differenti-
ation. They fail to express high affinity binding sites for IL-4 and accordingly do not respond to IL-4-
mediated signals. Cross-linking membrane lgM receptors or direct activation of protein kinase C via 
phorbolester induces IL-4 receptor expression and subsequent IL-4 reactivity. 
Key words: B lymphocytes, CD23, CLL, HLA class ll, IL-4, IL-4-receptor, membrane immuno-
globulin. 
JNTRODUCTION 
THERE is mueh evidenee that important signals 
required in B-eeil aetivation involve slg cross-linking 
whieh leads to and is dependent upon subsequent 
aetivation of PKC [ 1]. Another signalling system 
implieated in early B-eeil aetivation processes, using 
different, not yet clearly understood seeond mess-
enger systems, is IL-4 [2-4]. The expression of fune-
tional IL-4 reeeptors without a requirement for prior 
aetivation is a hallmark of immunoeompetent resting 
B eells [5, 6]. This finding, in addition to the definition 
of type 2 T-helper cells which seerete large amounts 
of IL-4 [7], has been taken as evidenee that IL-4 may 
play an important role in the early events of B-eeil 
activation, and may be even part of the eognate T-
helper signal. The slg as weil as the IL-4-induced 
signal caseade result in activation of genes whose 
produets seem to be involved in regulation of B-eeil 
proliferation [8, 9] or T-eell, B-eell eooperation [10-
14]. Both signals Iead to upregulation ofMHC class li 
expression on B eells [6, 15}. IL-4 induees enhaneed 
CD23 [5, 16] expression whereas slg eross-linking 
fails to do so. However, they are conneeted in that 
eostimulation with anti-Ig and IL-4 Ieads to hyper-
induetion of CD23 expression [5]. 
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Lymphocytic Iymphoma B cells are thought tobe 
in a developmental stage closely related to immu-
nocompetent, resting B cells [ 17]. Therefore we 
addressed the question how low grade NHL B eells 
ean respond to the two B-eeil aetivation pathways 
indueed either by eross-linking of the slg receptor 
or signals generated by IL-4. This is important for 
judging how a B-eeil tumor whieh is expanded in 
most eompartments ofthe immune system may inter-
act with the normal immune cells. Functional dis-
tinctions among B-cell tumors may be representative 
for normal B cells in partieular stages of aetivation 
or differentiation. Different B-eeil tu mors can be 
valuable tools for dissecting the signal cascades 
required for HLA dass II and CD23 expression and 
the cooperation between IL-4 and slg mediated sig-
nals. 
MATERIALSAND METHODS 
Reagents. Recombinant human IL-4 was purchased from 
Genzyme (IC Cemikalien, Munich, F.R.G.). Soluble goat 
F(ab')2-anti-IgM antiborlies were obtained from Jackson 
Laboratories (Dianova, Hamburg, F.R.G.), phorbol-
myristate-acetate (PMA). from Sigma (Deisenhofen, 
F.R.G.). Monoclonal antibodies, phycoerythrin (PE)- and 
ftuorescein-iso-thyocyanate (FITC)-labeled, were used: 
Leu12 (CD19), Leul (CD5), HLA-DR, HLA-DQ, Leu-
M3 (CD14), Leullc (CD16), Leul9 (CD56) (Becton-Dick-
inson, Heidelberg, F.R.G.) and 1088 (CD23) (Immu-
notech, Dianova, F.R.G.). Purified mAb against lgM, 
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kappa- and lambda-light chains ( Coulter, Krefeld, F. R. G.) 
were developed with a FITC- labeled F(ab'h-fragment of 
rabbit anti-mouse IgG (Jackson, Oianova). 
Lymphoma cells. Thirty-five patients were diagnosed as 
having a leukemic B-eeil Iymphoma of low malignancy, 
mainly CLL, immunocytoma and centrocytic Iymphoma 
(case 23, 33, 35). Cell surface phenotyping revealed a 
typical staining pattern (18]: CD19, CD5, HLA dass li-
positive with low expression of a light chain restricted 
surface lgM. Only case 22, 23, 31 and 35 stained negative 
for the CD5 antigen. Even though most cases were also 
CD23-positive. This antigen showed a considerable varia-
bility in staining intensity. The cell size distribution of the 
Iymphoma cells showed most of them only slightly larger 
than low density peripheral blood cells as judged by for-
ward scatter analysis (Table lc). No patient received any 
form of specific therapy. 
Cell preparation and culture conditions. Mononuclear 
cells (PBL) were isolated from heparinized blood (Heparin 
NOVO, Novo Industry, Mainz, F.R.G.) on Ficoll-Hy-
paque (Pharmacia, Freiburg. F.R.G.) density gradients. 
Part of the cells were cryopreserved using a programmable 
cell freezer (Sylab, Austria). Peripheral Iymphoma cells 
were T-depleted by rosetting with AET-treated sheep 
erythrocytes or anti-CD2, anti-CD4 and anti-CD8 coupled 
ox erythrocytes [19]. This depleted also most of NK cells 
and activated monocytes. FACS analysis revealed ~98% 
CD19-positive cells. Less than 1% stained with either T-
cell-specific (CD3), monocyte-specific (CD14) or NK-
specific (CD16, CD56) antibodies. Normal control B cells 
were purified from a spieen of a donor without hema-
tological disease. T cells, NK cells and activated monocytes 
were depleted by rosetting with anti-CD2, anti-CD4 and 
anti-C08 coupled ox erythrocytes. Monocytes were further 
depleted by avidin-coupled magnetic beads (Dynabeads 
M-280, Dianova) using biotinylated MY4 (CD14, Coulter) 
antibodies. This gave 95-98% CD19-positive cells. Purified 
B cells were cultured at 106/ml in RPMI 1640, containing 
10% fetal calf serum (Gibco, New York) in 24-well tissue 
culture plates (Falcon, Heidelberg, F.R.G.). 
Surface marker analysis. FACS analysiswas done after 
staining with monoclonal antiborlies using a F ACscan 
(Becton-Dickinson, Mountain View. CA, U.S.A.). Ten 
thousand viable cells were analyzed using forward/ 
sidescatter gating. 
Determination of 1 L-4 receptors. Recombinant IL~4 was 
radiolabeled using the enzymobead radioiodination 
reagent (Bio Rad, München, F.R.G.) [20]. Equilibrium 
binding of 1251-labeled IL-4 (1 251-IL-4) to human B-lym-
phoma cells was done according to Cabrillat [21]: purified 
Iymphoma cells (106) were washed and suspended in 200 f.ll 
RPMI, containing 2% bovine serum albumin (BS1) and 
0.2% sodium azide, with various concentrations of 1 1-IL-
4 either in the presence or absence of a 6000-fold excess 
of cold IL-4. After incubation for 2 h at 4°C, cells were 
washed twice. Cell bound 1251-IL-4 was separated from free 
I25J-IL-4 by centrifugation through 200 f.ll silicon oil. The 
number of binding sites per cell was calculated from the 
linear portion of Scatchard plots. 
RESULTS 
Tables 1 a--c give an overview of the studied Iym-
phoma cells. The data are presented as values of 
mean ftuorescence intensity for the respective 
directly labeled mAb. We think it important to pro-
vide the raw data for the different stimuli, since it 
reveals the heterogeneity in baseline expression of 
CD23 and HLA class II and more importantly in 
responsiveness between the different Iymphoma B 
cells. 
Responsiveness to slg and P MA -mediated signals 
We analyzed the expression of HLA class II, CD23 
molecules and increase in cell size upon stimulation 
with soluble F(ab'h-anti-IgM antibodies or direct 
activation of PKC via PMA. A maximum response 
was usually seen between 10 and 30 ~g/ml F(ab'h-
anti-IgM and 1-5 ng/ml PMA, after a culture period 
of 30-40 h (not shown). As judged from the FACS 
staining profiles, positive responses incJuded usually 
more than 80% of the cells. 
In contrast to normal control spienie B cells only 
14 out of 35lymphoma cases showed a reproducible, 
significant increase of HLA dass II expression in 
response to soluble F(ab')2-anti-IgM antiborlies 
(Table lb: cases 22-24. 26-35). The reactivity is 
not related to the intensity of basal HLA dass II 
expression. An appreciable cell enlargement is only 
seen in three cases ( patients 33-35) upon slg cross-
linking (Table 1c). Apart from these, most of the 
other studied Iymphoma cells increased their cell 
size upon PMA stimulation but failed to do so with 
F(ab'h-anti-IgM antibodies (data not shown). How-
ever, the majority of cases respond to PMA with an 
increase in HLA dass Ilexpression (Table 1b). Thus 
the events of the intracellular signaHing cascade distal 
to PKC activation seem to function in most Iym-
phoma cases. 
Soluble F(ab'h-anti-IgM antiborlies induce no 
appreciable increase in CD23 expression on normal 
or on the studied Iymphoma cells, whereas PMA is 
able to induce CD23 on the same cells (Table 1). 
Responsiveness to I L-4-mediated signals 
Since we could enhance HLA class li and CD23 
expression in all studied Iymphoma cells (via PMA 
or anti-Ig), we asked if the IL-4-induced signal cas-
cade is also operating in the Iymphoma cells and 
results in the expression of these particular gene 
products. Therefore we measured HLA class li and 
CD23 expression upon Stimulation with IL-4. 
Tables la and b show that 31 out of 35 Iymphomas 
are responsive to IL-4 without prior activation. IL-4 
can upregulate the expression of CD23 or HLA class 
11 molecules. In most cases both antigens could be 
coordinately upregulated similar to normal control B 
cells (NC, Tables 1a, b). We did not observe any 
dose or kinetic differences between the Iymphomas. 
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TABLE la. REGULATION OF CD23 EXPRESSION (MFI)* ON LEUKEMIC B CELLS 
Case Nil Anti-IgMt IL-4* Anti-IgM + IL-4 PMA§ PMA + IL-4 
1 21 17 143 137 229 552 
2 18 15 121 118 n.d.ll n.d. 
3 30 31 105 121 159 232 
4 23 24 72 71 n.d. n.d. 
5 28 26 63 n.d. n.d. n.d. 
6 22 19 59 55 120 234 
7 20 18 55 52 66 131 
8 10 10 32 29 127 262 
9 8 5 27 25 115 284 
10 9 9 30 n.d. n.d. n.d. 
11 5 4 30 35 25 337 
12 4 3 21 21 222 676 
13 4 5 18 23 10 101 
14 6 7 15 15 52 155 
15 9 8 21 20 32 94 
16 8 6 17 18 32 66 
17 11 11 23 24 157 274 
18 13 12 25 29 84 158 
19 4 n.d. 7 n.d. 60 114 
20 12 12 15 15 n.d. n.d. 
21 7 5 8 10 91 235 
22 6 6 40 289 40 514 
23 5 6 38 93 31 98 
24 5 4 23 22 83 410 
25 43 40 97 157 n.d. n.d. 
26 8 7 19 40 166 224 
27 4 7 18 26 108 316 
28 4 4 14 13 47 70 
29 7 8 16 50 72 343 
30 3 3 5 6 5 58 
31 2 2 3 3 4 20 
32 5 4 6 7 27 77 
33 4 5 6 204 18 178 
34 3 4 4 96 17 97 
35 8 9 8 567 62 429 
NC~ 7 6 34 191 30 649 
Purified B cells were cultured at 106 cells/ml for 40 h. Expression of CD23 was determined by 
ftow cytometry. The Iymphoma cases were grouped for reproducible responsiveness to anti-IgM 
antibodies. Cases 1-21 show no anti-Ig reactivity, whereas cases 22-35 do respond. Cases 33-35 
are separated from the latter group because of lacking IL-4 responsiveness. 
* Mean fluorescence intensity. linear scale. 
t F(ab')z-anti-IgM 10 ~g/ml. 
:j: riL--4 100 U/ml. 
§ PMA 3 ng/ml. 
II Not done. 
~ Purified B cells of a healthy control person. 
The maximum effect is reached between 10 and 
100 V /ml IL-4 after a 32-40 h culture period ( data 
not shown). We never saw a significant size increase 
upon IL-4 in normal control B cells or in Iymphoma 
cells (Table lc). 
However there is heterogeneity in the response 
pattern to IL-4. Most cases upregulate CD23 and 
HLA dass II molecules coordinately, but five out of 
35 cases show a dissociation in that they are con-
sistently induced for elevated HLA dass li 
expression, while failing to upregulate CD23 (Table 
1: cases 19-21, 30, 31). Three out of 35 Iymphomas 
(cases 33-35) show no response to IL-4 at all, neither 
for HLA dass II nor for CD23 expression, even 
though both antigens can be upregulated in these cells 
by F(ab')2-anti-IgM antibodies or PMA, respectively 
(Tables la, b). 
Enhancement of JL-4-induced CD23 expression upon 
costimulation with anti-lg or PMA 
It has been reported that costimulation with 
insolubilized anti-IgM antibodies and IL~4 leads to 
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TABLE 1b. REGULATION OF HLA CLASS II EXPRESSION (MFI)* ON LEUKEMIC 8 CELLS 
Case Nil Anti-IgMt IL-4+ Anti-lgM + ILA PMA§ PMA + IL·4 
1 .. 319 324 500 486 730 806 
2** 1811 2035 1755 1762 n.d.ll n.d. 
3** 482 504 685 654 602 629 
4tt 143 146 223 211 n.d. n.d. 
5tt 334 365 478 n.d. n.d. n.d. 
6** 685 626 1382 1553 1963 2350 
7tt 292 213 523 453 723 679 
8tt 150 154 193 173 194 153 
9tt 820 780 1055 1219 1176 1420 
lütt 576 531 873 n.d. n.d. n.d. 
11 .. 1596 1470 1746 1610 2813 n.d. 
12** 644 673 1346 1348 1295 1027 
13** 1827 1860 1778 1700 1670 1786 
14tt 271 280 922 1037 764 982 
15** 666 706 1071 1058 829 1044 
16tt 281 231 578 519 567 698 
17 .. 1034 973 1778 1911 2458 2350 
18tt 791 874 906 1065 965 1186 
19** 342 n.d. 637 n.d. 858 843 
20** 973 1036 1486 1472 n.d. n.d. 
21tt 362 312 710 677 1018 1252 
22** 528 1640 1275 1685 1928 1009 
23** 538 1446 615 973 1309 1298 
24** 1197 1472 2207 2329 2548 2690 
25tt 644 638 679 730 n.d. n.d. 
26tt 2048 2652 3046 2958 2661 2680 
27** 1520 2060 2113 2288 2262 3128 
28** 720 1241 1124 1134 1208 1176 
29** 1370 2329 1554 1778 1395 1358 
30** 445 1610 835 1554 1459 1433 
31tt 813 1091 1395 1472 1843 1778 
32tt 770 964 851 828 931 1000 
33** 1461 2490 1440 2468 1345 n.d. 
34** 306 1700 349 1346 757 874 
35** 599 1472 610 1234 604 n.d. 
NC~tt 1578 2585 2180 2210 2453 2848 
Purified 8 cells were cultured at 106 cells/ml for 40 h. Expression of HLA class II was determined 
by flow cytometry. The Iymphoma cases were grouped for reproducible responsiveness to anti-IgM 
antibodies. Cases 1-21 show no anti-Ig reactivity, whereas cases 22-35 do respond. Cases 33-35 are 
separated from the latter group because of lacking IL-4 responsiveness. 
• Mean ftuorescence intensity, linear scale. 
t F(ab')2-anti-IgM 10 J.lg/ml. 
t riL-4 100 U/ml. 
§ PMA 3 ng/ml. 
II Not done. 
~ Purified 8 cells of a healthy control person. 
•• HLA-DR. 
tt HLA-DQ. 
markedly enhanced CD23 expression on normal B 
cells (5]. Table la shows that costimulation with 
soluble F(ab')z-anti-IgM can also enhance IL-4-
induced CD23 expression. This enhanced CD23 
expression operates in Iymphoma cells which also 
respond to anti-Ig with enhanced HLA class II 
expression. Therefore the missing signal transmission 
in anti-Ig non-reactive Iymphomas affects also co-
stimulation of CD23 expression with IL-4 as weil as 
stimulation of class II expression. 
Again, direct Stimulation of PKC by PMA caused a 
potentiating effect on IL-4-induced CD23 expression 
in alllymphomas, indicating that the signal cascade 
distal from PKC activation is regularly functioning. 
For HLA class II expression we did not observe any 
costimulatory enhancement by anti-Ig and IL-4. 
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TABLE lc. REGULATION OF CELL DIAMETER (FSC)* ON LEUKEMIC ß CELLS 
Case Nil Anti-IgMt IL-4+ Anti-IgM + IL-4 PMA§ PMA + IL-4 
33 84 108 84 n.d. 120 n.d. 
34 87 111 90 115 136 123 
35 75 100 76 103 143 n.d. 
NCII 78 114 81 117 119 116 
Purified B cells were cultured at 106 cells/ml for 40 h. Cell size was determined by flow cytometry. 
Cases 3~35 lack IL-4 responsiveness. 
"' Forward scatter. 
t F(ab')z-anti-lgM 10 J.Lg/ml. 
+ riL-4 100 U/ml. 
§ PMA 3 ng/mJ. 
II Purified B cells of a healthy control person. 
T ABLE 2. INDUCTION OF HlGH AFFINITY IL-4 RECEPTORS 
ON B LYMPHOMA CELLS 
Case Conditions IL-4R/ce11s 
34 Freshly isolated Not detectable 
33 Freshly isolated Not detectable 
33 18 h culture in medium Not detectable 
33 18 h culture with anti-IgM* 180 
33 18 h culture with PMA t 190 
21 18 h culture in medium 140 
21 18 h culture with PMA t 380 
Binding experiments were done as shown in Fig. 3. 
Numbers of IL-4 receptors were caJculated from Scatchard 
plot analysis. Lymphoma cells were depleted ofT cells and 
were 98% CD19-positive. 
• F(ab')2-anti-I~M was used at 10 J.Lg/ml. 
t PMA at 3 ngjml. 
/nduction of IL-4 reactivity in IL-4 non-reactive Iym-
phoma cells 
Three out of 35 Iymphoma cases (Nos 33-35), 
which stained negative for CD23, repeatedly failed 
to respond to IL-4 as judged by enhancement of 
HLA dass II expression (Fig. 1, case 33) or CD23 
expression (Table la). However, cross-linking slg via 
F(ab')2-anti-IgM antiborlies induces expression of 
HLA class II molecuJes with coordinate upregulation 
of all three subgroups HLA-DR, -DQ and -DP (Fig. 
1). CD23 expression can be induced by PMA. Co-
stimulation of these cells with F(ab'h-anti-IgM 
antiborlies and IL-4 result in high expression of CD23 
even though both stimuli alone failed to do so (Table 
la). 
We then analyzed the time sequence of the two 
required signals in these Iymphoma cells. Figure 2 
demonstrates a two stage culture experiment with 
Iymphoma case 33: during the first culture period 
the cells were cultured either with medium, IL-4, 
or F(ab'h-anti-Ig antibodies for 18 h. Cells were 
then recovered, extensively washed and recultured 
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FIG. 1. Purified B Iymphoma cells of case No. 33 were 
cultured at 106/ml with either medium ( ----), soluble 
F(ab'h-anti-lgM at 10 ~g/ml ( .... ) or 100 U/ml IL-4 
( ..... ).After 40 h the expression of HLA-DR, -DQ, -DP 
and CD19 was determined by flow cytometry. 
with and without IL-4 and/or F(ab'h-anti-IgM anti-
bodies. The expression of the CD23 antigen was 
determined after 7 h and 23 h in the 2nd culture 
period. The result indicates that prestimulation with 
F(ab'h-anti-IgM antibodies Ieads to responsiveness 
for the IL-4 signal. In the anti-Ig prestimulated cel1s, 
more than 80% of the cells show significant CD23 
expression upon IL-4. In addition, the IL-4-induced 
CD23 expression can be detected much earlier on 
these cells. At 7 h after the IL-4 signal, anti-Ig 
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FIG. 2. Purified B cell tumor cells of case No. 33 were 
cultured in a 1st culture period of 18 h with medium, 
F(ab')2-anti-IgM antibodies at 10 Jlg/ml, or IL-4 at 100 U/ 
ml. Subsequently cells were washed three tirnes and recul-
tured with medium, F(ab'h-anti-IgM 10 lJ,g/ml, IL-4 
100 U/ml or both. Seven hours (A) and 23 h (B) later 
the surface expression of CD23 was determined by flow 
cytometry. The solid line depicts cells cultured and treated 
in parallel always in culture medium. The dotted line 
corresponds to cells treated as given above the diagram: 
1st culture period/2nd culture period. 
prestimulated cells have increased their CD23 
expression, while cells which get anti-Ig antibodies 
and IL-4 tagether at the beginning of the second 
culture period show no CD23 expression. After 23 h 
in the second culture, both groups have reached 
their maximal stimulation. There is no further CD23 
increase up to 40 h in the second stage ( data not 
shown). IL-4 prestimulation followed by F(ab'h-
anti-lgM induces no significant CD23 expression. 
This indicates that case 33 has no baseline IL-4 reac-
tivity, and mlg cross-linking induces IL-4 reactivity in 
these cells. Cases 34 and 35 show a similar reactivity 
pattern. 
Expression and induction of /L-4 receptors in Iym-
phoma B cells 
The Iack of IL-4 responsiveness of cases 33-35 may 
be due to a failure of IL-4 receptor expression or 
may indicate a requirement for IL-4 receptor acti-
vation for signal transmission. We therefore deter-
mined the number of IL-4 receptors on the Iymphoma 
cells by binding of radiolabeled IL-4. Figure 3 illus-
trates typical equilibrium binding data for 1251-IL-4 
to a IL-4 responsive Iymphoma (case 1, Table 1b). 
Scatchard plot analysis yielded 750-800 specific bind-
ing sites per cell. 
Recently it has been shown that insolubilized anti-
lgM antibodies upregulate the number of high affinity 
IL-4 receptors on normal human B cells [22]. Sirni-
lady we demoostrate elevated numbers of IL-4 recep-
tors after PMA Stimulation. As shown in Table 2, 
unstimulated cells of B Iymphoma case 21 express 190 
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FIG. 3. Equilibrium binding of 1251-IL-4 to purified Iym-
phoma cells of case No. 1 as described in Materials and 
Methods. The inset illustrates Scatchard plot analysis of 
specific binding. 
with PMA they upregulate their IL-4 receptor num-
ber to 380 per cell. This corresponds to the functional 
data, where these cells respond without prior acti-
vation to IL-4 with enhanced HLA dass II expression 
and costimulation with PMA and IL-4 enhances IL-
4 reactivity as judged by elevated CD23 expression 
(Tables la, b). 
The cells of the IL-4 non-responsive Iymphomas 
cases 33 and 34 repeatedly failed to show specific 
binding of 1251-IL-4 under comparable conditions 
(Table 2). However, after stimulation of Iymphoma 
case 33 for 18 h with either soluble F(ab'h-anti-IgM 
or PMA, we can detect 180 and 190 IL-4 receptors 
per cell, respectively. This parallels the induction of 
IL-4 reactivity by these stimuli (Fig. 2). These data 
indicate that the IL-4 non-responsive Iymphoma cells 
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fail to express IL-4 receptors. Cross-linking slg with 
soluble anti-IgM antiborlies or direct activation of 
PKC with PMA induces expression of IL-4 receptors 
rendering these cells responsive to the IL-4 signal. 
DISCUSSION 
lt has been shown that certain neoplastic B cells 
or B-eeil lines can respond to IL-4. Some CLL B 
cells upregulate CD23 expression upon stimulation 
with IL-4 (23-25), and some Burkitt Iymphoma cell 
lines respond to IL-4 with coordinate expression of 
CD23 and HLA dass li molecules (26]. We extend 
these observations of IL-4 responsiveness by com-
paring expression of CD23 and HLA dass II mol-
ecules and determining the influence of slg or 
phorbolester-mediated signals upon IL-4 respon-
siveness and IL-4 receptor expression. These signals 
and inducible gene products have been shown in a 
nurober of systemstobe involved in B-eeil activation/ 
differentiation [8, 9, 24, 27-30] and T celi-B cell 
cooperation [10--14]. 
To avoid phenotypes produced by in vitro selection 
of a cellline, we used only cells freshly isolated from 
the peripheral blood. The Iymphoma cases were not 
selected for reactivity in our activation system. They 
were studied in the order of their presentation and 
were required only to have a peripheral Iymphoma 
cell count of over 10 000 cells/mm3• 
Our results indicate a remarkable heterogeneity in 
responsiveness to the employed signals which could 
not be related to the phenotype of the Iymphoma 
cells. The majority of the Iymphomas respond to IL-
4 by coordinate upregulation of CD23 and HLA dass 
II molecules as has been shown for some Burkitt 
Iymphoma celllines (26]. Thus, like normal tonsillar 
[5] or spienie B cells (NC Tables la-c), they express 
functional IL-4 receptors without a requirement for 
prior activation. The pattern of responsiveness is not 
dependent from the source of B cells, since we have 
not observed fundamental differences between B 
cells isolated from the blood, tonsils or spieen in 
healthy persons [unpublished]. 
The upregulation of CD23 can be shown in Iym-
phoma cells which express low amounts of CD23 
as weH as in cells which already stain for CD23. 
Accordingly, high affinity receptors can be demon-
strated by binding of radiolabeled IL-4. The various 
Iymphoma cells express between 200 and 900 IL-4 
receptors per cell (Fig. 3, Table 2 and (T. 
Lebrobeeher, unpublished data]) which corresponds 
weil to the nurober of IL-4 receptors on normal, 
resting B cells [22]. Therefore most neoplastic B cells 
resemble normal, resting immunocompetent B ceiJs, 
which may argue that these Iymphoma cells represent 
a dosely-related developmental stage. 
CD23 expression has been used to define de-
velopmental B-cell stages, since it is not expressed 
on immature B cells and is lost after isotype switching 
of mature B cells [31-33]. This developmental analy-
sis has been extended by analyzing the dissociation 
of the IL-4 response as measured by CD23 or HLA 
dass II expression. Waldschmidt and coworkers have 
shown that immature, murine lgM+ /IgD+ B cells 
respond to IL-4 by enhanced HLA class II 
expression, but fail to upregulate CD23. These 
authors even suggest that this response pattern would 
better define the self-renewing "sister-B-celllineage" 
[32]. The Iack of coordinated expression of CD23 
and HLA dass II molecules can also be seen in 
a group of the Iymphomas which we studied. For 
example, cases 19-21, 30, 31 (Tables 1a-c) respond 
quite weil with elevated HLA dass II expression in 
response to IL-4. However, we could not see CD23 
induction with IL-4 in these Iymphoma cells even 
though CD23 could be upregulated with PMA. This 
is independent of the IL-4 dose employed ( data not 
shown). These types of Iymphoma cells may allow 
the dissection of the signal cascades required for 
MHC dass II and CD23 expression. 
slg signalling results at least in part from Stimu-
lation of inositol phospholipid breakdown and acti-
vation of PKC (34-36]. Therefore phorbolesters can 
be used to "shortcut" the sig-mediated signal and 
substitute for anti-Ig antiborlies in certain activation 
events [37J. Accordingly, PMA did induce HLA dass 
II molecules and acted, similar to soluble F( ab'h-
anti-IgM in normal spienie B cells, to enhance 
responsiveness to IL-4 as indicated by hyperinduction 
of CD23 in essentially ali the Iymphomas studied 
(Tables la-c). This is probably due to enhanced IL-
4 receptor expression, which we demonstrated in 
these Iymphomas in response to PMA (Table 2). 
However, PMA displays an additional signal qual-
ity in relation to anti-IgM antiborlies since PMA 
alone Ieads in normal as weil as in the studied Iym-
phoma cells to enhanced CD23 expression whereas 
soluble F(ab'h-anti-IgM antiborlies regularly fail to 
do so (Tables la-c). This is in centrast to a report by 
Ghaderi et a/. [38] who find in 8 out of 9 CLL cases 
a decreased CD23 expression upon TPA Stimulation. 
The difference may be related to the indirect roset-
ting technique used for measuring CD23 expression. 
Three Iymphoma cases (Nos 33-35) did not show 
any reactivity to IL-4. This was not due to a defect 
in the machinery for the expression of HLA dass II 
or CD23 molecules, since HLA dass li expression 
was inducible by membrane Ig cross-linking and 
CD23 by PMA (Tables la. b). In fact all three major 
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HLA class II subclasses HLA-DR, -DQ and -DP 
could be upregulated in these cells by cross-linking 
slg (Fig. 1). 
Binding studies with iodinated IL-4 failed to dem-
oostrate any specific binding, indicating a Iack of IL-
4 receptor expression on cells of cases 33 and 34 
{Table 2). However, signalling through slgM by sol-
uble F(ab')ranti-IgM antiborlies induces specific IL-
4 binding sites in a frequency usually found on resting 
normal B cells (22}. Also, direct activation of PKC 
via PMA resulted in expression of IL-4 receptors, 
pointing to the centrat role of PKC in the regulation 
ofiL-4 receptor expression. Parallel to the expression 
of ILA receptors on the cell surface we can dem-
oostrate IL-4 responsiveness by analyzing subsequent 
CD23 expression. This is also reftected in the kinetic 
data showing that anti-Ig preactivated B cells increase 
CD23 expression following addition of IL-4 earlier 
as compared to B cells receiving the anti-Ig and IL-
4 signals at the same time (Fig. 2). 
These experiments support the hypothesis that 
hyperinduction of CD23 upon concomitant anti-Ig 
and IL-4 signaHing is due to enhanced expression of 
IL-4 receptors following the slg-mediated signals, 
rather than receptor activation. 
The IL-4 receptor-negative Iymphomas showed no 
distinctive phenotype of surface markers usually used 
for phenotyping B-eeil Iymphoma cells. In particular 
CDS expression did not distinguish them from 
the other B-eeil Iymphomas of low malignancy. How-
ever, all stained negative for CD23. They are 
infrequent in as much as we only found 3 in 35 studied 
cases. They seem to define a distinct differentiation 
stage of B cells because they not only Iack IL-4 
receptors and responsiveness but show distinctive 
functional behavior. They respond weil upon slg 
cross-linking with cell size enlargement, HLA class 
li expression and expression of functional IL-4 recep-
tors, features most low grade Iymphomas lack. 
Future studies will be required to show how they fit 
into the differentiation scheme of B cells and whether 
or not they correspond to a distinct, self-renewing B-
celllineage, which has been extensively characterized 
in the mouse system (39}. 
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